endocrinology MCQ (SBA): ADA Standards of Care (2025): Cardiovascular Disease and Risk Management

Instant feedback + full explanation. One question, done properly.

MediumADA recommends adding a GLP‑1 RA with proven CV benefit in patients with ASCVD and/or obesityADA Standards of Care (2025): Cardiovascular Disease and Risk Managementendocrinology

A 70-year-old man with DM2 and A1c 7.4% is on metformin and SGLT2 inhibitor. He has obesity and ASCVD. Which add-on is appropriate?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.

endocrinology MCQ: ADA Standards of Care (2025): Cardiovascular Diseas